TY - JOUR
T1 - Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults
AU - Silverberg, Jonathan I.
AU - Gelfand, Joel M.
AU - Margolis, David J.
AU - Boguniewicz, Mark
AU - Fonacier, Luz
AU - Grayson, Mitchell H.
AU - Ong, Peck Y.
AU - Chiesa Fuxench, Zelma C.
AU - Simpson, Eric L.
N1 - Funding Information:
Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association (NEA) and sponsored by Sanofi Genzyme and Regeneron. The sponsor had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Conceptualization: JIS; Data Curation: JIS, JMG, DJM, LF, MB, ELS, MHG, PYO, ZCCF; Formal Analysis: JIS; Funding Acquisition: Allergy and Asthma Foundation of America; Investigation: JIS, JMG, DJM, LF, MB, ELS, MHG, PYO, ZCCF; Methodology: JIS, JMG, DJM, LF, MB, ELS, MHG, PYO, ZCCF; Project Administration: Allergy and Asthma Foundation of America; Resources: Allergy and Asthma Foundation of America; Writing - Original Draft Preparation: JIS; Writing - Review and Editing: JIS, JMG, DJM, LF, MB, ELS, MHG, PYO, ZCCF
Funding Information:
JIS served as a consultant and/or advisory board member for Abbvie, AnaptysBio, Asana, Arena, Boehringer-Ingelheim, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, Regeneron-Sanofi, and Realm, receiving honoraria; was a speaker for Regeneron-Sanofi; and received research grants from GlaxoSmithKline. JMG served as a consultant for BMS, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics and Novartis. JMG is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma. JMG is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology. ZCCF has served as a consultant for the National Eczema Association and the Asthma and Allergy Foundation, receiving honoraria; receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Tioga and Vanda and Menlo pharmaceuticals and Realm Therapeutics for work in atopic dermatitis; and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Regeneron and/or Sanofi. DJM is the chair of the data monitoring committee for all Sanofi clinical trials of dupilumab and has received independent research funding to his institution from the National Institute of Health and Valeant to study atopic dermatitis. He is a consultant for Pfizer. MB has received research funding from Regeneron and consulted for Regeneron, Sanofi-Genzyme, and Eli Lilly. LF has served as consultant and advisory board member for Regeneron, receiving honoraria; and received research and educational grants from Genentech, Regeneron, Baxter, and Pfizer. MHG is a board member of AAFA and chair for the AAFA Medical Scientific Council and has served on advisory boards for AstraZeneca, Genentech, and Novartis. ELS is an investigator for Eli Lilly Co, Galderma, Leo Pharmaceutical Co, Merck, Pfizer, and Regeneron Pharmaceuticals, Inc and a consultant with honorarium for AbbVie Inc, Boehringer-Ingelheim, Dermavant, Eli Lilly Co, Incyte, Leo Pharmaceutical Co, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc, and Sanofi Genzyme. PYO is a co-investigator of Atopic Dermatitis Research Network and has consulted for Pfizer and Theravance and has received research funding from Regeneron.
Funding Information:
Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association (NEA) and sponsored by Sanofi Genzyme and Regeneron.
Publisher Copyright:
© 2019 The Authors
PY - 2019/10
Y1 - 2019/10
N2 - Quality-of-life assessments are not standardized in atopic dermatitis (AD). We sought to determine the validity of the Short Form (SF)-12, a generic quality-of-life assessment, in AD and compare its measurement properties with the Dermatology Life Quality Index (DLQI). A cross-sectional, population-based study of 3,495 adults was performed, including 602 adults who met the modified United Kingdom Working Party Criteria for AD. The SF-12 mental component score and the SF-Six Dimension (SF-6D) had a strong correlation with each other and moderate inverse correlations with the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring Atopic Dermatitis, the Patient-Oriented Scoring Atopic Dermatitis–itch, the Patient-Oriented Scoring Atopic Dermatitis–sleep, and the Numerical Rating Scale of pain (Pearson correlations, P < 0.0001 for all). The SF-12 mental component score and the SF-6D showed good discriminant validity as judged by the analysis of variance and receiver operating curves. The SF-12 physical component score had weak correlations with AD severity assessments and poor discriminant validity. The DLQI had better convergent and discriminant validity than the SF-12. The SF-12 and the DLQI showed good internal consistency (Cronbach alpha, 0.89 and 0.94, respectively). Differential item functioning was found for items in the SF-12 and the DLQI. Floor effects were observed for the DLQI but not for the SF-12 mental component score, the SF-12 physical component score, and the SF-6D. Severity thresholds were selected. In conclusion, the SF-12 mental component score and the SF-6D showed good validity in AD but inferior construct validity compared with the DLQI.
AB - Quality-of-life assessments are not standardized in atopic dermatitis (AD). We sought to determine the validity of the Short Form (SF)-12, a generic quality-of-life assessment, in AD and compare its measurement properties with the Dermatology Life Quality Index (DLQI). A cross-sectional, population-based study of 3,495 adults was performed, including 602 adults who met the modified United Kingdom Working Party Criteria for AD. The SF-12 mental component score and the SF-Six Dimension (SF-6D) had a strong correlation with each other and moderate inverse correlations with the Patient-Oriented Eczema Measure, the Patient-Oriented Scoring Atopic Dermatitis, the Patient-Oriented Scoring Atopic Dermatitis–itch, the Patient-Oriented Scoring Atopic Dermatitis–sleep, and the Numerical Rating Scale of pain (Pearson correlations, P < 0.0001 for all). The SF-12 mental component score and the SF-6D showed good discriminant validity as judged by the analysis of variance and receiver operating curves. The SF-12 physical component score had weak correlations with AD severity assessments and poor discriminant validity. The DLQI had better convergent and discriminant validity than the SF-12. The SF-12 and the DLQI showed good internal consistency (Cronbach alpha, 0.89 and 0.94, respectively). Differential item functioning was found for items in the SF-12 and the DLQI. Floor effects were observed for the DLQI but not for the SF-12 mental component score, the SF-12 physical component score, and the SF-6D. Severity thresholds were selected. In conclusion, the SF-12 mental component score and the SF-6D showed good validity in AD but inferior construct validity compared with the DLQI.
UR - http://www.scopus.com/inward/record.url?scp=85067885495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067885495&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2019.03.1152
DO - 10.1016/j.jid.2019.03.1152
M3 - Article
C2 - 31009616
AN - SCOPUS:85067885495
SN - 0022-202X
VL - 139
SP - 2090-2097.e3
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 10
ER -